Clinical trials: Atezolizumab-bevacizumab
Hepatocellular Carcinoma (HCC)
Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
This single-center prospective observational cohort study aims to evaluate the predictive value of peripheral blood-based biomarkers for treatment response in patients with hepatocellular carcinoma (HCC) receiving first-line…
- Trial name
- NCT07734857
- Testing
- No intervention (observational study)
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it…
- Trial name
- NCT02997228
- Testing
- Atezolizumab, Bevacizumab, Biospecimen Collection
- Where
- 445 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma
This study is evaluating the safety and potential effectiveness of adding folic acid to atezolizumab plus bevacizumab as first-line treatment for adults with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT07835737
- Testing
- Folic Acid, Atezolizumab & Bevacizumab
- Volunteers
- 78 people
- Sponsor
- West China Hospital
Glioblastoma, Recurrence Tumor
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma.
- Trial name
- Phenix (NCT07263438)
- Testing
- Trimipramine, Cohort 1: Atezolizumab, Bevacizumab
- Where
- 7 sites in Switzerland
- Volunteers
- 59 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Hepatocellular Carcinoma
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for…
- Trial name
- NCT06294548
- Testing
- Valemetostat, Atezolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Hepatocellular Carcinoma
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Atezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for…
- Trial name
- NCT05751343
- Testing
- TACE-HACI, plus atezolizumab-bevacizumab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Venous Thrombosis
A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
The treatment strategies for HCC with PVTT is still controversial, and differ substantially between the west and the east. According to western guidelines, including those of the EASL, BCLC, and AASLD, PVTT is regarded as a…
- Trial name
- TALENTOP (NCT04649489)
- Testing
- Atezolizumab & Bevacizumab, Surgery followed by atezolizumab and bevacizumab
- Where
- 23 sites in China
- Volunteers
- 501 people
- Sponsor
- Jia Fan